Literature DB >> 24283299

microRNA profiling in patients with abdominal aortic aneurysms: the significance of miR-155.

Erik Biros1, Corey S Moran1, Yutang Wang1, Philip J Walker2, John Cardinal3, Jonathan Golledge.   

Abstract

AAA (abdominal aortic aneurysm) is a potentially life-threatening late-onset degenerative condition. miRNAs (microRNAs), the small non-coding RNA molecules that regulate gene expression, have been shown previously to be associated with a broad range of human pathologies, including cardiovascular diseases. The aim of the present study was to identify AAA-associated miRNAs potentially contributing to AAA pathology. We analysed the expression of 124 miRNAs within AAA biopsies and serum of ten patients undergoing AAA repair, and serum from ten age- and sex-matched subjects without AAA, using the FlexmiR™ MicroRNA Assay. RNA extracted from the site of main AAA dilatation (AAA body) was compared with that extracted from the macroscopically non-dilated neck of the AAA (AAA neck). Similarly, RNA extracted from the serum of AAA patients (AAA serum) was compared with that extracted from age- and sex-matched controls (control serum). qPCR (quantitative real-time PCR), Western blot analysis and histology were performed using an independent set of six paired AAA body and neck biopsies to examine the validity of findings. Seven miRNAs were up-regulated [>2-fold difference, FDR (false discovery rate) <0.5] within AAA biopsies, of which miR-155 was the most differentially expressed (11.32-fold, FDR=0.414). This finding was confirmed by qPCR with the median relative expression of miR-155 being 3.26 and 0.63 within AAA body and AAA neck biopsies respectively (P=0.031). Circulating miR-155 was also increased in AAA patients compared with controls, with a 2.67-fold up-regulation at borderline significance (FDR=0.554). Two immunologically important miR-155 target genes, CTLA4 (cytotoxic T-lymphocyte-associated protein) and SMAD2, were assessed and found to be significantly down-regulated within AAA bodies compared with AAA necks (P=0.032 and P=0.026) as determined by qPCR and Western blotting respectively. Histology demonstrated dense accumulation of T-lymphocytes within the adventitial and outer medial layers of AAA body, but not neck tissue. The results of the present study suggest that miR-155 is overexpressed in AAA with potential implications in the pathogenesis of the condition.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24283299     DOI: 10.1042/CS20130599

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  23 in total

Review 1.  The emerging roles of long noncoding RNAs in common cardiovascular diseases.

Authors:  Xiaoying Jiang; Qilan Ning
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

2.  Patients with bicuspid and tricuspid aortic valve exhibit distinct regional microrna signatures in mildly dilated ascending aorta.

Authors:  Sebastian Albinsson; Alessandro Della Corte; Azra Alajbegovic; Katarzyna K Krawczyk; Ciro Bancone; Umberto Galderisi; Marilena Cipollaro; Marisa De Feo; Amalia Forte
Journal:  Heart Vessels       Date:  2017-01-19       Impact factor: 2.037

3.  MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing pro-inflammatory macrophage activation.

Authors:  Hai-Tao Yang; Li-Li Li; Song-Nan Li; Jin-Tao Wu; Ke Chen; Wei-Feng Song; Guo-Bao Zhang; Ji-Fang Ma; Hai-Xia Fu; Sheng Cao; Chuan-Yu Gao; Juan Hu
Journal:  Cardiovasc Diagn Ther       Date:  2022-06

4.  MicroRNA-129-5p inhibits vascular smooth muscle cell proliferation by targeting Wnt5a.

Authors:  Yiming Zhang; Zhao Liu; Min Zhou; Changjian Liu
Journal:  Exp Ther Med       Date:  2016-09-06       Impact factor: 2.447

Review 5.  Epigenetics and Peripheral Artery Disease.

Authors:  Jonathan Golledge; Erik Biros; John Bingley; Vikram Iyer; Smriti M Krishna
Journal:  Curr Atheroscler Rep       Date:  2016-04       Impact factor: 5.113

6.  Differential gene expression in human abdominal aortic aneurysm and aortic occlusive disease.

Authors:  Erik Biros; Gabor Gäbel; Corey S Moran; Charlotte Schreurs; Jan H N Lindeman; Philip J Walker; Maria Nataatmadja; Malcolm West; Lesca M Holdt; Irene Hinterseher; Christian Pilarsky; Jonathan Golledge
Journal:  Oncotarget       Date:  2015-05-30

7.  Efficacy of brief behavioral counselling by allied health professionals to promote physical activity in people with peripheral arterial disease (BIPP): study protocol for a multi-center randomized controlled trial.

Authors:  Nicola W Burton; Zanfina Ademi; Stuart Best; Maria A Fiatarone Singh; Jason S Jenkins; Kenny D Lawson; Anthony S Leicht; Yorgi Mavros; Yian Noble; Paul Norman; Richard Norman; Belinda J Parmenter; Jenna Pinchbeck; Christopher M Reid; Sophie E Rowbotham; Lisan Yip; Jonathan Golledge
Journal:  BMC Public Health       Date:  2016-11-09       Impact factor: 3.295

Review 8.  MicroRNAs: Novel Players in Aortic Aneurysm.

Authors:  Xian-ming Fu; Yang-zhao Zhou; Zhao Cheng; Xiao-bo Liao; Xin-min Zhou
Journal:  Biomed Res Int       Date:  2015-06-28       Impact factor: 3.411

9.  Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology.

Authors:  Albert Busch; Martin Busch; Claus-Jürgen Scholz; Richard Kellersmann; Christoph Otto; Ekaterina Chernogubova; Lars Maegdefessel; Alma Zernecke; Udo Lorenz
Journal:  Int J Mol Sci       Date:  2016-01-12       Impact factor: 5.923

10.  Targeting MicroRNA-192-5p, a Downstream Effector of NOXs (NADPH Oxidases), Reverses Endothelial DHFR (Dihydrofolate Reductase) Deficiency to Attenuate Abdominal Aortic Aneurysm Formation.

Authors:  Kai Huang; Taro Narumi; Yixuan Zhang; Qiang Li; Priya Murugesan; Yusi Wu; Norika Mengchia Liu; Hua Cai
Journal:  Hypertension       Date:  2021-06-28       Impact factor: 9.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.